The p73 gene is a p53 homologue located at 1p36-33, a region submitted to deletions in breast cancer (BC) and putatively imprinted. To study whether p73 was associated with breast carcinogenesis, loss of heterozygosity (LOH), allele expression and transcript levels were assessed in 59 BC, including 39 BC presenting no in¯ammatory symptoms (NBC) and 20 in¯ammatory BC (IBC). IBC is a rare but aggressive form of cancer with a very poor prognosis. Normal breast epithelium (BE) and lymphocytes from patients were used as controls. StyI polymorphism generating GC and/or AT alleles was used to select 22 heterozygous patients. p73 LOH was signi®cantly higher in IBC than in NBC [®ve of eight cases (62%) versus two of 14 cases (14%); Fisher's exact test, P=0.05]. p73 was biallelically expressed in all BE. In contrast, 12 of 16 (75%) BC were monoallelically expressed, showing that allele silencing was signi®cantly associated with breast carcinogenesis (P=0.012), AT being the preferential silent allele (10 out of 12 tumours). p73 mRNA levels in NBC and IBC were two-and threefold lower than in BE, respectively, suggesting that decreased expression could be related to tumour aggressiveness. In conclusion, LOH, allele silencing and decreased expression of the p73 gene may play a role in breast carcinogenesis. Oncogene (2000) 19, 5413 ± 5418.
Keywords: p73; monoallelic expression; in¯ammatory breast carcinoma The p73 gene, the ®rst p53 homologue (Kaghad et al., 1997) , speci®es a protein structurally similar to the p53 protein within its transactivating, DNA-binding, and oligomerization domains. Alternative splicing of exon 13 in p73 gene generates two transcripts, isoforms a and b, diering in their carboxy-terminal domain (Kaghad et al., 1997) . In p73 ectopically overexpressed tissue culture, the p73 protein can upregulate p53-responsive genes involved in cell-cycle arrest or apoptosis (Kaghad et al., 1997; Jost et al., 1997) , thereby eliciting biological functions similar to those of p53. Loss of heterozygosity (LOH) spanning a large chromosomal region (1p32-1pter) (BieÁ che et al., 1994) , which includes the p73 genomic locus (1p36-3), represents the most frequent (40%) genetic alteration in invasive BC. This evidence strongly suggests that p73 gene alterations could participate in BC tumour progression as a tumour suppressor gene. However, recent data showed that p73 somatic mutations were very rare in solid tumours (Han et al., 1999) , particularly in BC (Shishikura et al., 1999; Zaika et al., 1999) . The fact that p73 gene was monoallelically expressed in the SK-N-SH neuroblastoma cell line suggests that p73 inactivation may result from speci®c loss of the expressed allele.
BC shows unusual patterns with respect to the p53 gene, known to play a crucial role in regulating cell growth and preventing malignant transformation of cells. Although p53 loss and/or inactivation is a frequent even in human cancers (up to 50%) (BeÂ roud and Soussi, 1998) , only 30% of BCs exhibit high levels of nuclear p53 protein associated with mutations (Levine et al., 1991; Moll et al., 1992; Riou et al., 1993) . Although 30% of in¯ammatory BC (IBC) also show p53 mutation, 40% show nuclear exclusion of p53 wild type associated with cytoplasmic staining (Moll et al., 1992) and 30% have undetectable staining, suggesting a very particular p53 gene status in this rare type of locally advanced invasive BC.
Based on these grounds, we investigated putative p73 gene involvement in breast carcinogenesis by studying its genomic and expression status in invasive ductal BC and the corresponding patient's normal tissue. To address whether p73 gene status is related to aggressiveness of the disease, we compared tumour specimens of a series of in¯ammatory BC (IBC), known to be the most aggressive form of all BC (Shittoor and Swain, 1998) with those of non-in¯ammatory BC (NBC) predominantly including early-stage tumours.
We analysed p73 LOH in BC using StyI restriction fragment length polymorphism (RFLP) that consists of a double nucleotide substitution in exon 2 and generates the so-called`GC allele' and`AT allele' (Kaghad et al., 1997) . Fifty-nine BC consisting of 20 IBC (all classi®ed at T4d) and 39 NBC (T1 and T2, n=32; T3 and T4, n=7) were analysed and compared with matched normal breast epithelium (BE) or normal lymphocytes used as controls. Twenty-two patients (37%) were found to carry both GC/AT alleles, whereas 36 patients were homozygous for the GC allele (61%) and only one patient was homozygous for the AT allele (Table 1) indicating that the homozygous genotype AT/AT is very rare. The over-representation of the GC/GC genotype did not appear to be linked to the population of BC patients, as similar results were obtained in healthy blood donors (Table 1) .
In patients showing the GC/AT genotype, p73 gene LOH was found in seven of 22 BC (32%) including ®ve of eight (62%) IBC and two of 14 (14%) NBC (Table 2, Figure 1 ), indicating that LOH was signi®cantly more frequent in IBC than in NBC (Fisher's exact test, P=0.05). There was no preferential loss of either the GC allele or AT allele. In the six BC-derived cell lines tested, p73 heterozygosity (GC/AT) was found in the MDA-MB 231 cell line, whereas the other ®ve cell lines (MCF7, SKBR3, ZR 75.1, T47D and CAL 18A) were characterized by a homozygous or hemizygous (GC) allele. Analysis of three other¯anking loci at the 1p36-3 chromosomal sub-band, i.e., methylenetetrahydrofolate reductase gene (MTHFR) (Goyette et al., 1994) and two loci with a variable number of tandem repeats (D1S76 and D1S80) (Peter et al., 1992) indicated that LOH at the 1p36-3 locus is not restricted to the p73 gene (data not shown) but spans this locus.
Mutation at the p73 gene spanning exons 4 to 10 was investigated by direct cDNA sequencing in seven BC specimens (®ve IBC and two NBC): no mutation was detected in any of the tumours, even in the ®ve BC showing p73 LOH (four IBC and one NBC) ( Table 3) . Both exons 5 and 6 polymorphisms, previously observed in other human tissues, were detected in two IBC specimens and at exon 9 in another IBC specimen. These data indicate that the p73 gene does not play the role of a canonical suppressor gene in the breast epithelium. p53 gene sequencing of these seven tumours (exons 1 to 11) revealed two missense mutations at codons 175 and 237 and a silent mutation at codon 213 in IBC (Table 3) . (n=20) 0.20 12 (60) 8 (40) 0 Invasive breast carcinoma specimens were obtained from 59 patients. All tumours were invasive ductal carcinomas. Thirty-nine tumours were non-in¯ammatory BC (NBC) and 20 tumours corresponded to a very aggressive form of BC essentially diagnosed on the basis of clinical symptoms of in¯ammation and denoted as in¯ammatory breast cancer (IBC). Breast epithelial tissue (n=8) adjacent to breast tumours was also obtained at surgery. Lymphocytes (L) from the same patients (n=51) and from healthy blood donors (n=34) were obtained from blood by fractionation in a Ficoll gradient. DNA was prepared using the guanidinium isothiocyanate-CsCl gradient method (Ahomadegbe et al., 1995) . For p73 analysis, genomic DNA was ampli®ed as previously described (Kaghad et al., 1997) . PCR products were submitted to restriction polymorphism analysis using StyI endonuclease which generates`GC allele' and/or`AT allele' Detection of p73 LOH was performed in patients showing the GC/AT genotype. The relative amount of each allele was determined by densitometer analysis using the Joyce-Loebl chromoscan densitometer. Tumours were scored as disclosing LOH when the loss of more than 30% of one allele was observed as compared with controls (normal BE or lymphocytes from the corresponding patients). For analysis of the allelic expression, RNA was extracted by guanidinium isothiocyanate-CsCl gradient method, then incubated with DNase RNase-free (GibcoBRL) and puri®ed by RNAzol (Bioprobe). cDNA was obtained as previously described (Ahomadegbe et al., 1995) . RT ± PCR products were digested with StyI. The original paper by Kaghad et al. (1997) suggested that p73 was submitted to genomic imprinting in the SK-N-SH heterozygous neuroblastoma cell line. However, from several reports, the allelic expression status appears to be unclear in normal human cells and tumours, including BC (Kaghad et al., 1997; Mai et al., 1998a; Zaika et al., 1999) . Analysis of p73 allelic expression in 16 BC specimens and normal BE specimens (six cases) and lymphocytes (nine cases) obtained from the same patients was performed by RT ± PCR spanning from exon 1 to exon 5 and subsequent analysis for StyI RFLP (Kaghad et al., 1997) . Biallelic expression of the p73 gene was consistently observed in all specimens of normal BE (Figure 2, Tables 2 and 4) . Firstly, we studied BC showing LOH and found that the p73 gene was monoallelically expressed by the retained allele. In the tumour from patient no. 3, the allele corresponding to the deleted allele (AT allele) was weakly expressed and is denoted as GC/ AT in Table 2 . This expression was likely due to normal cells expressing both alleles and contaminating the tumour. We secondly considered BC showing no LOH and noted that p73 was expressed by both alleles in four cases and by one allele, the GC allele, in two cases (Table 4 ). The other ®ve BC presented a marked imbalance of expression in favour of the GC allele. The presence of small amounts of AT allele in these tumours was most likely due to contamination by normal BE. We therefore considered the BC showing a strong imbalance in favour of GC allele to be only expressed by this allele. To sum up, p73 was monoallelically expressed in 12 out of 16 BC (75%) and biallelically expressed in four BC (25%), indicating that AT allele silencing is associated with BC carcinogenesis (Fisher's exact test P=0.012) and pointing out imprinting in a subset of tumours. Monoallelic expression of p73 was observed in all IBC tested (®ve out of ®ve, 100%) and in seven out of 11 (64%) NBC. However, this dierence was not signi®cant, probably due to the small number of Figure 1 Example of loss of heterozygosity (LOH) of the p73 gene in breast cancer (BC). MTHFR gene (Goyette et al., 1994) and D1S76 and D1S80 loci (Peter et al., 1992) mapping in the vicinity at band 1p36.3 were studied for comparison. Control tissue was normal breast epithelium (BE). BC presented deletions of the AT allele for p73, allele b for MTHFR, allele a for D1S76 and D1S80 Figure 2 Examples of allelic expression of p73 gene in breast cancer (BC) and lymphocytes (L) or normal breast epithelium (BE) from the same patients. Patients number 1, 2, 11, 13, and 12 are shown in Table 2 . RNAs were reverse transcribed and cDNA was digested with StyI. Informative specimens yielded three cDNA fragments. Two out of these three fragments represent the GC and AT alleles. The third fragment is a common restriction product. A and B are BC specimens with monoallelic expression of the GC and AT allele, respectively. Tumours from patients 1 and 2 showing deletion of the GC allele (Table 2 ) displayed a monoallelic expression of the AT allele. Tumours from patients 11, 13 and 12 did not show allele deletions. In the BC from patient 12, p73 was expressed by both GC and AT alleles, in the BC from patient 11, p73 was monoallelically expressed by the GC allele and in the BC from patient 13, p73 was preferentially expressed by the GC allele. The presence of the AT allele in this tumour was most likely due to BE contaminating the tumour Polymorphisms previously observed in other human tissues were detected at both exons 5 and 6 (patients 5 and 17) and at exon 9 (patient 7) tumours analysed, which decreased the power of the statistical test. Similar results were obtained by analysing shorter PCR products, spanning from exon 1 to exon 3 (Mai et al., 1998b ) (data not shown). For lymphocytes obtained from nine patients, the p73 gene was biallelically expressed in six cases and monoallelically expressed in three cases (GC allele). As a control of our p73 data, we also analysed the allelic expression of the MTHFR gene in eight tumours found to be informative for both genes (data not shown): biallelic expression of the gene was observed in the ®ve BC without LOH. The three BC with MTHFR LOH showed expression of the retained allele. This gene was biallelically expressed in lymphocytes (®ve cases) and normal BE (three cases), as previously reported for human tissues (Goyette et al., 1994) . In conclusion, p73 monoallelic expression was very frequently observed in the BC studied, regardless of their LOH status (P=0.012), strongly suggesting that total or partial AT allele silencing could be involved in the development of BC.
To test whether monoallelic expression could in¯uence the overall expression of p73, we assessed p73 transcript levels in invasive BC and normal BE by semiquantitative RT ± PCR using the GAPDH gene as control. PCR assays were performed using primers in spanning the p73 DNA binding domain (DBD) (exons 6 to 8), and the C-terminus domain, a domain subject to splicing (Kaghad et al., 1997) . Conditions were set up to yield quantities of RT ± PCR products according to a linear response. For technical convenience, we determined the p73 transcript level of the MCF7 cell line that was only expressed by the GC allele as the control value and considered its level to be equal to 10 arbitrary units (a.u.). The overall mRNA expression of BC obtained from 11 homozygous patients was also studied. In the DBD, the p73 transcript levels were found to be higher in BE (mean value of seven specimens, 22+11 a.u.) than in BC (mean values of 18 NBC and nine IBC specimens, 11.8+5.8 a.u. and 9+4 a.u., respectively (Figures 3 and 4) . We compared the p73 mRNA levels in matched BE-BC specimens obtained from seven patients and found lower levels in all BC. A 2 ± 6-fold greater decrease was observed in four BC. However, the mRNA level did not appear to be correlated with allele expression, as low expression levels were observed as well as in monoallelically than in biallelically expressed tumours. Similar transcription levels were obtained with primers spanning the p73 Cterminus domain (data not shown), thereby excluding an alteration of C-terminal splicing (de Laurenzi et al., 1998) as a cause of the decreased transcript level observed in BC. Moreover, low p73 mRNA level was observed in lymphocytes (mean value of nine specimens: 6+5 a.u.) indicating that p73 expression is tissue-dependent. Our data dier from those reported in BC and other tumours. Shishikura et al. (1999) reported interindividual dierences in mRNA levels for eight BC patients, but no dierence between BE and BC for each patient. In another recent study, Zaika et al. (1999) compared p73 mRNA levels of BC with a basal level of expression corresponding to the mean level found in 17 specimens of normal tissues of various origins. They reported overexpression in 38% of invasive BC (5 ± 25-fold the baseline level) and normal' expression in the other tumours. However, this method of quanti®cation seems to be inadequate because of the multiple origin of the normal tissues analysed (kidney, thyroid, lymphocytes, ovary, placenta, breast, neutrophils and breast) showing a very dierent pattern of p73 expression from that of breast epithelium. In lung, renal, and bladder tissues, mRNA levels were found to be higher in tumours than in corresponding normal tissues (Mai et al., 1998a,b; Yokomizo et al., 1999) .
No correlation was observed between p73 LOH and allelic expression and various clinical and laboratory parameters: TNM stage, histological type, axillary node status, hormone receptor status, extent of in situ component, stromal reaction, presence of lymphatic or venous emboli, clinical response to initial chemotherapy (Table 5 ). The p73 status of IBC patients did not appear to have any prognostic or predictive signi®-cance, due to the small number of informative patients. It might suggest that, although p73 LOH is likely to be a crucial event in the onset of in¯ammatory breast In parenthesis, the number of specimens. b`G C allele' was deleted in these two tumours Figure 3 Characteristic p73 transcript pro®le obtained by RT ± PCR in MCF7 cell line, L, BE and BC (NBC and IBC). GAPDH gene was used as internal control. p73 cDNA was ampli®ed using primers sense (5' TGG ATG ACC CTG TCA CCG GC 3') and antisense (5' TGC TCC CGG TAG TGG TCC TCA 3') located on the DBD domain of the gene (exon 6 to 8). In a preliminary study and for semiquantitative analysis of p73 transcript levels, ampli®cation was performed by one cycle steps from 25 to 40 cycles and a kinetic ampli®cation curve was plotted, showing that a plateau phase was reached after 37 cycles. p73 transcript levels were therefore determined after 33 cycles within the exponential phase. GAPDH cDNA was ampli®ed after 23 cycles and used as internal controls. A multiplex ampli®cation was dicult to perform due to the high levels of GAPDH transcripts and low levels of p73 transcripts. Therefore, for each sample, 2 ml of ampli®ed p73 cDNA and 2 ml of ampli®ed GAPDH cDNA were mixed and electrophoresed on polyacrylamide gels cancer, alternative pathways could lead to the same clinical phenotype. In NBC, however, p73 LOH is an uncommon event (two of 14 patients). Patients with p73 LOH shared the same clinical and pathologic features (Table 5) with aggressive, node-positive carcinomas. One of these patients had a short-term metastatic relapse, but, unfortunately, the other patient was lost to follow-up. If we consider the overall population of BC patients assessable for survival regardless of their TNM stage, ®ve of the six patients with p73 LOH ultimately died of their disease versus only six of the 14 patients without p73 LOH (Fisher's exact test, P=0.15); six of the nine patients with monoallelic expression died of their disease versus one of the four patients with biallelic expression (Fisher's exact test, P=0.27). New evidence for alternative splicing and dierential promoter usage in the N-terminus of p73 gene in various tissues has been described (Yang et al., 2000) , leading to expression of N-truncated variants deprived of the transactivation activity of p73 which, in turn, would act as dominant negative factors towards p53 and p73 transcriptional activities. It is crucial to identify which isotype is down-regulated, as it could determine the decreased transcription detected in the DBD. The stoichiometric dierences between these N- Figure 4 p73 expression levels in lymphocytes, normal breast epithelium, and breast carcinomas (non in¯ammatory BC and in¯ammatory BC). The transcript levels were assessed by semiquantitative RT ± PCR. The p73 mRNA level from MCF7 cell line expressing the GC allele was used as control value (10 arbitrary units, a.u.). Densitometric quanti®cation was performed using the Joyce-Loebl chromoscan. Specimens are presented in the order of their expression levels. Eleven homozygous tumours were studied in addition to heterozygous tumours Table 2 truncated isotypes and full-length a and b isotypes in normal tissues and BC are currently under investigation (Ahomadegbe, in preparation) since these variants very probably elicit opposite biological functions. From a clinical point of view, our study stresses the marked and signi®cant decrease of p73 mRNA levels in in¯ammatory BC (IBC). IBC, which is classi®ed as T4d, accounts for 2 ± 4% of all BC and is the most aggressive form of locally advanced BC, which is solely de®ned by clinical symptoms, i.e., diuse brawny induration and presence of erythema and oedema (peau d'orange) of the skin of the breast probably due to dermal lymphatic vessel obstruction (Shittoor and Swain, 1998; Beahrs et al., 1992) . p73 LOH seems to be an adverse prognostic factor in breast carcinoma and is associated with T4d stage. Although it is unlikely that p73 alteration constitutes the unique molecular determinant of in¯ammatory tumours, this criterion is of outstanding importance, since few pathological or even molecular characteristics have yet been correlated with this very particular and uncommon subset of breast cancers. p73-de®cient mice exhibit in¯ammation of many organs (Yang et al., 2000) , suggesting a role for p73 in the in¯amma-tory response. Remarkably, a proin¯ammatory cytokine, macrophage migration inhibitory factor (MIF), was recently shown to overcome p53 tumour suppressor activity by inhibiting its transactivation function (Hudson et al., 1999) . The natural history of in¯ammatory diseases indicates that, in a given tissue, in¯ammatory loci are characterized by high rates of cell death and compensatory proliferation in neighbouring uncommitted host cells. Chronic bypass of p53 function, in a context of reactive oxidants released by activated T cells and macrophages, leads to enhanced proliferation, de®cient response damage and accumulation of oncogenic mutations (CordonCardo and Prives, 1999) . Strikingly, IBC show alterations of both p53 (Moll et al., 1992) and p73 genes; these phenomena oer a molecular clue to the oncogenesis of IBC, by suggesting that both p53 and p73 eectors involved in growth arrest and/or apoptosis are not functional in the most aggressive form of BC.
